# Leukocytes carrying Clonal Hematopoiesis of Indeterminate Potential (CHIP) Mutations invade Human Atherosclerotic Plaques

Short title: CHIP in atherosclerotic plaque

Moritz von Scheidt<sup>1,2</sup>, Sabine Bauer<sup>1,2</sup>, Angela Ma<sup>3</sup>, Ke Hao<sup>3</sup>, Thorsten Kessler<sup>1,2</sup>, Baiba Vilne<sup>2,4,5</sup>, Ying Wang<sup>6</sup>, Chani J. Hodonsky<sup>7</sup>, Saikat K.B. Ghosh<sup>8</sup>, Michal Mokry<sup>9,10</sup>, Hua Gao<sup>11</sup>, Kenji Kawai<sup>8</sup>, Atsushi Sakamoto<sup>8,12</sup>, Juliane Kaiser<sup>13</sup>, Dario Bongiovanni<sup>14,15</sup>, Julia Fleig<sup>1</sup>, Lilith Oldenbuettel<sup>1</sup>, Zhifen Chen<sup>1,2</sup>, Aldo Moggio<sup>1,2</sup>, Hendrik B. Sager<sup>1,2</sup>, Judith S. Hecker<sup>16</sup>, Florian Bassermann<sup>16</sup>, Lars Maegdefessel<sup>2,17</sup>, Clint L. Miller<sup>18</sup>, Wolfgang Koenig<sup>1,2</sup>, Andreas M. Zeiher<sup>19</sup>, Stefanie Dimmeler<sup>19</sup>, Matthias Graw<sup>13</sup>, Christian Braun<sup>13</sup>, Arno Ruusalepp<sup>20,21,22</sup>, Nicholas J. Leeper<sup>10,23</sup>, Jason C. Kovacic<sup>24,25,26</sup>, Johan L.M. Björkegren\*<sup>3,21,27</sup>, Heribert Schunkert\*<sup>1,2</sup>

#### **Affiliations**

- 1 Department of Cardiology, German Heart Center Munich, Technical University Munich, Munich, Germany.
- 2 Deutsches Zentrum für Herz- und Kreislaufforschung (DZHK), Partner Site Munich Heart Alliance, Munich, Germany.
- 3 Department of Genetics and Genomic Sciences, Institute of Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, USA.
- 4 Bioinformatics Lab, Riga Stradiņš University, Riga, Latvia.
- 5 SIA Net-OMICS, Riga, Latvia.
- 6 Department of Pathology and Laboratory Medicine, Centre for Heart Lung Innovation, University of British Columbia, Vancouver, Canada.
- 7 Center for Public Health Genomics, University of Virginia, Charlottesville, VA, USA.
- 8 CVPath Institute, Inc, Gaithersburg, USA.
- 9 Laboratory of Experimental Cardiology, Department of Cardiology, University Medical Center Utrecht, University Utrecht, Utrecht, Netherlands.
- 10 Central Diagnostics Laboratory, University Medical Center Utrecht, Utrecht, The Netherlands
- 11 Division of Vascular Surgery, Department of Surgery, Stanford University School of Medicine, Stanford, USA.
- 12 Division of Cardiology, Internal Medicine III, Hamamatsu University School of Medicine, Hamamatsu, Japan.
- 13 Institute of Legal Medicine, Faculty of Medicine, LMU Munich, Germany.
- 14 Department of Internal Medicine I, Cardiology, University Hospital Augsburg, University of Augsburg, Germany.
- 18 Department or Cardiovasculat Medicine, "High antas Charles and Humanitas University, Rozzano, Milan, Italy.

<sup>\*</sup>Authors contributed equally

- 16 Department of Medicine III, Technical University of Munich (TUM), Klinikum rechts der Isar, Munich, Germany.
- 17 Department for Vascular and Endovascular Surgery, Klinikum Rechts der Isar, Technical University Munich, Munich, Germany.
- 18 Center for Public Health Genomics, Department of Public Health Sciences, Department of Biochemistry and Molecular Genetics, University of Virginia, Charlottesville, VA, USA.
- 19 Institute for Cardiovascular Regeneration, Goethe University Frankfurt am Main, Frankfurt am Main, Germany.
- 20 Department of Cardiac Surgery, The Heart Clinic, Tartu University Hospital, Tartu, Estonia.
- 21 Clinical Gene Networks AB, Stockholm, Sweden.
- 22 Institute of Clinical Medicine, Faculty of Medicine, Tartu University, Tartu, Estonia.
- 23 Stanford Cardiovascular Institute, Stanford University, Stanford, USA.
- 24 Victor Chang Cardiac Research Institute, Darlinghurst, Australia.
- 25 St. Vincent's Clinical School, University of New South Wales, Sydney, Australia.
- 26 Cardiovascular Research Institute, Icahn School of Medicine at Mount Sinai, New York, USA.
- 27 Department of Medicine, Huddinge, Karolinska Institutet, Karolinska Universitetssjukhuset, Stockholm, Sweden.

#### **Corresponding authors**

Prof. Dr. med. Heribert Schunkert, MD; ORCID 0000-0001-6428-3001 and

Dr. Dr. med. Moritz von Scheidt, MD; ORCID 0000-0001-7159-8271

Deutsches Herzzentrum München (German Heart Center Munich)

Klinik für Herz- und Kreislauferkrankungen

Lazarettstr. 36

D-80636 München

Telephone: +49-89-1218-2849

Fax: +49-89-1218-4013

Email: <a href="mailto:scheidt@dhm.mhn.de">schunkert@dhm.mhn.de</a>; <a href="mailto:moritz.scheidt@tum.de">moritz.scheidt@tum.de</a>;

# **Total word count**

9,590 (including Title Page, Abstract, Text, References, Tables and Figure Legends)

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

Background: Leukocyte progenitors derived from clonal hematopoiesis of undetermined potential (CHIP) are associated with increased cardiovascular events. However, the prevalence and functional relevance of CHIP in coronary artery disease (CAD) are unclear, and cells affected by CHIP have not been detected in human atherosclerotic plaques. Methods: CHIP mutations in blood and tissues were identified by targeted deep-DNAsequencing (DNAseq: coverage >3,000) and whole-genome-sequencing (WGS: coverage >35). CHIP-mutated leukocytes were visualized in human atherosclerotic plaques by mutaFISH<sup>TM</sup>. Functional relevance of CHIP mutations was studied by RNAseg. Results: DNAseq of whole blood from 540 deceased CAD patients of the Munich cardlovaScular Studles biObaNk (MISSION) identified 253 (46.9%) CHIP mutation carriers (mean age 78.3 years). DNAseg on myocardium, atherosclerotic coronary and carotid arteries detected identical CHIP mutations in 18 out of 25 mutation carriers in tissue DNA. MutaFISHTM visualized individual macrophages carrying *DNMT3A* CHIP mutations in human atherosclerotic plaques. Studying monocyte-derived macrophages from Stockholm-Tartu Atherosclerosis Reverse Networks Engineering Task (STARNET; n=941) by WGS revealed CHIP mutations in 14.2% (mean age 67.1 years). RNAseg of these macrophages revealed that expression patterns in CHIP mutation carriers differed substantially from those of non-carriers. Moreover, patterns were different depending on the underlying mutations, e.g. those carrying TET2 mutations predominantly displayed upregulated inflammatory signaling whereas ASXL1 mutations showed stronger effects on metabolic pathways. Conclusions: Deep-DNA-sequencing reveals a high prevalence of CHIP mutations in whole blood of CAD patients. CHIP-affected leukocytes invade plaques in human coronary arteries. RNAseq data obtained from macrophages of CHIP-affected patients suggest that proatherosclerotic signaling differs depending on the underlying mutations. Further studies are necessary to understand whether specific pathways affected by CHIP mutations may be targeted for personalized treatment.

- 27 Key words: aging, atherosclerotic cardiovascular disease, clonal hematopoiesis of
- 28 indeterminate potential, coronary artery disease, inflammation

# Introduction

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

Clonal hematopoiesis of undetermined potential (CHIP) is a common age-related condition and potential precursor to hematological neoplasms. CHIP is defined as presence of a clonally expanded hematopoietic cell caused by a somatic mutation in individuals without hematologic abnormalities. Such mutations, predominantly in the epigenetic regulators DNMT3A, TET2 or ASXL1, have been identified in bone marrow and blood, but these cells have never been definitively detected in human atherosclerotic plaques. 1 Whole-exome sequencing has shown that CHIP is practically absent in individuals younger than 30 years of age, whereas it is present in 20% to 30% of individuals aged 50 to 60 years. 1, 2 The use of more sensitive sequencing techniques and access to bone marrow has demonstrated that small clones are quite common in middle-aged individuals.3, 4 CHIP carriers have an increased risk of cardiovascular events and mortality, including early onset and aggravated progression of coronary artery disease (CAD), myocardial infarction, stroke, aortic valve calcification and chronic ischemic heart failure.<sup>5-8</sup> The higher the burden of CHIP-affected cells measured by the variant allele frequency (VAF), the higher was the reported risk of adverse events.<sup>5-8</sup> Indeed, detection of CHIP in peripheral blood may serve as a biomarker for adverse outcomes in individuals with cardiovascular diseases (CVDs). Experimental studies deciphered the first mechanistic insights explaining the associations of CHIP mutations with CVD. Fuster et al. demonstrated that transplantation of bone marrow containing a Tet2 loss-of-function mutation in hematopoietic cells in mice mimics the human situation of CHIP including increased numbers of activated macrophages (measured by upregulation of *IL-1β*) found in plaques. Aggravated atherosclerosis was triggered by activation of the inflammatory cascade in these cells. Further, in-vitro LPS-stimulation of macrophages carrying somatic mutations led to increased expression of IL-6, the downstream mediator of the inflammasome complex, and IL-1\(\beta\).9

Our current understanding is that driver mutations in *DNMT3A*, *TET2* or *ASXL1* lead to expansion of clones in the bone marrow resulting in increased numbers of cells with epigenetic alterations in the peripheral blood. These changes result in increased expression of genes associated with inflammatory pathways, which in turn may stimulate the progression of atherosclerosis. Here we studied the prevalence of CHIP in DNA sequence data, whether CHIP-mutated leukocytes invade atherosclerotic plaques in human arteries and whether macrophages isolated from CAD patients carrying specific CHIP mutations also present with specific CAD signatures by examining macrophage RNA-expression profiles and associated clinical phenotypes (Figure 1).

# **Materials and Methods**

# **Ethics approval**

The institutional review board and Ethics Committee of the Technical University of Munich, Germany, approved the protocol of MISSION (2018-325-S-KK – 08/22/2018). The use of human STARNET samples has been approved by the Estonian Bioethics and Human Research Committee (Ministry of Social Affairs) (IRB 2771T,17 – 12/01/2018) and by the written informed consent of the donor, in accordance with the guidelines and regulations for the use of biological material of human origin. Both studies were conducted in accordance with the provisions of the Declaration of Helsinki and the International Conference on Harmonization guidelines for good clinical practice.

#### Data accessibility

Data used in this study are available in permanent repositories. Human data from MISSION can be requested by qualified researchers at the German Heart Center Munich from the corresponding author. Human data from STARNET are accessible through the Database of Genotypes and Phenotypes (dbGAP).

#### MISSION – cohort and sample description

The Munich cardlovaScular Studles biObaNk (MISSION) was started in 2019 and comprises cardiovascular relevant tissues, including blood and plasma, liver, myocardium, coronary, and carotid samples from >950 deceased individuals sampled in FFPE and fresh frozen at -80°C. Prior to freezing and sequencing, all tissues are washed and subsequently conserved in PBS/DMSO. MISSION provides the full spectrum of coronary phenotypes from healthy to severe atherosclerosis. DNA of leukocytes and cardiovascular tissues was analyzed by deeptargeted-amplicon-sequencing. The leukocytes derived from whole blood, and the analyzed tissue encompassed the proximal part of atherosclerosis-affected left anterior descending (LAD) coronary, atherosclerosis-affected left carotid artery and left ventricular heart muscle.

#### DNA extraction from blood and tissue

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

For the extraction of DNA from whole blood, the Maxwell DNA Blood Kit (Promega) was used. For this purpose, whole blood was incubated for 20 minutes at room temperature under rotation (Rotating shaker, Kisker Biotech, Germany). Then, 300µl of whole blood was mixed with 300µl of lysis buffer and 30µl of proteinase K. The mixture was incubated under rotation for 30 minutes at room temperature, followed by another 30 minutes at 65°C and 600rpm in a heat block (Thermomixer comfort, Eppendorf, Germany). Every 10 minutes, incubation was performed at 1500rpm for approximately 1 minute. DNA extraction from human coronary artery, carotid and left ventricle was performed based on 50mg of frozen tissue samples. Perivascular tissue was removed from arteries and tissues were washed in 1x PBS. Isolation was performed based on a modified Maxwell DNA Blood kit (Promega) protocol. After mechanical homogenization (TissueLyser II, Qiagen, The Netherlands) of the tissues in 300µl incubation buffer, 1-thioglycerol and proteinase K were added. The mixture was incubated for 4 hours at 65°C and 600rpm in a heat block (Thermomixer comfort, Eppendorf, Germany). This was followed by the addition of 300µl of lysis buffer and re-incubation for 10 minutes at 600rpm. Finally, the batches (blood and tissue) were transferred to the first well of the cartridge included in the kit. After addition of the plunger, the cartridge was inserted into the Maxwell RSC 48 system. The supplied elution tubes (0.5ml) were filled with 65µl of elution buffer and also inserted into the instrument. Finally, the predefined Maxwell DNA Blood protocol was selected and DNA was isolated in around 37 minutes. Isolated DNA was measured fluorometrically with a Qubit 3.0 (ThermoScientific).

# Sample preparation and DNA extraction

Whole blood and cardiovascular tissues were analyzed by deep-DNA-sequencing to detect hematopoietic stem cell derived mononuclear cells with CHIP mutations in cardiovascular relevant tissues. Samples were sequenced using an Illumina TruSeq Custom sequencing panel at the Munich Leukemia Laboratory. The concentration of extracted genomic DNA was determined with a Qubit dsDNA HS assay kit (Life Technologies) and then diluted to 25ng/µl

in 30µl of nuclease free water. A depth of more than 1000 detections per gene was targeted for sequencing to reliably detect CHIP-mutated hematopoietic cells in whole blood, atherosclerosis-affected coronary and carotid artery, and myocardium of the left ventricle.

# **Deep-DNA-sequencing**

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

A previously established panel containing 594 amplicons in 56 genes was used in the Illumina TruSeq Custom Amplicon Low Input assay.<sup>6</sup> To allow improved identification of low allele frequency variants, double-strand sequencing was performed. In addition, 6-bp unique molecular identifiers (UMIs) were included in the target-specific primers. Prior to sequencing, pooled libraries were diluted and denatured according to the NextSeq System Denature and Dilute Libraries Guide (Illumina). 1% PhiX DNA was added. Pooled libraries were sequenced with the NextSeq 500 sequencer (Illumina) using the NextSeq 500/550 Mid Output, Version 2 kit (300 cycles) according to the manufacturer's instructions. The sequencer was run in pairedend sequencing mode with a read length of 2x150bp and an index read length of 2x8bp. The BCL files were demultiplexed and converted to FASTQ files using the FASTQ Generation tool on BaseSpace (Illumina). The average coverage of the samples was >3,000 per gene. The variants were further validated on the basis of being reported in the literature and/or the Catalogue of Somatic Mutations in Cancer (https://cancer.sanger.ac.uk/cosmic) and ClinVar (https://www.ncbi.nlm.nih.gov/clinvar). The 56 gene panel was adapted after screening the first n=192 individuals to a custom 13 gene panel comprising ASXL1, CALR, CBL, DNMT3A, JAK2, MPL, PPM1D, SF3B1, SRSF2, TET2, TP53, U2AF1 and ZRSR2, thereby covering almost 90% of known CHIP mutations. The 13 gene panel followed the same analysis pipeline.

#### Visualization of specific CHIP mutations in human plaques

Mutation specific Fluorescence In Situ Hybridization (mutaFISH<sup>™</sup>) analysis on *DNMT3A* gene was performed on 3-5µm thick tissue sections from human coronary and carotid arteries of patients with known mutation (c.2245C>T and c.2333T>G) in the *DNMT3A* gene. In situ rolling circle technology was performed using custom made dual color *DNMT3A* mutation and

wildtype specific FISH probes (Abnova, Taiwan). The detailed protocol used for pretreatment, reverse transcription, hybridization, amplification and signal detection is provided in the supplement. It is based on the manufacturers protocol for mutaFISH<sup>TM</sup> RNA Accessory Kit and the protocol for muta FISH<sup>TM</sup> HER2wt RNA probes with some modifications in target retrieval, washing buffer and incubation. Negative controls were used to establish unspecific binding and background. All reagents were prepared with RNAse free (DEPC treated) water/PBS. For hybridization a Boekel Scientific Slide Moat oven was used. Images were acquired at the ZEISS Axioscan 7 slide scanner and analysis was performed using Zeiss Software ZEN 3.5 blue edition.

# **STARNET – Study and sample description**

To further study the ability of CHIP-mutated leukocytes to invade atherosclerotic plaques and to identify their biological impact we leveraged the Stockholm-Tartu Atherosclerosis Reverse Networks Engineering Task (STARNET) study datasets. Briefly, patients with CAD undergoing coronary artery bypass grafting (CABG; n=941) donated multiple tissue samples that included liver, skeletal muscle, subcutaneous fat, visceral abdominal fat, atherosclerotic aortic wall, internal mammary artery and whole blood as previously described. After quality control, WGS data of all 941 STARNET individuals were suitable for downstream CHIP analysis.

#### Whole genome sequencing

DNA from whole blood was isolated with the QIAmp DNA Blood Midi kit (Qiagen). DNA qualities were assessed with the Agilent 2100 Bioanalyzer system (Agilent Technologies, Palo Alto, CA). Library preparation and sequencing were performed at Beijing Genomic Institute (BGI). Genomic DNA samples that passed quality control were randomly fragmented by Covaris technology and 350bp fragments were selected. End repair of DNA fragments was performed and an "A" base was added at the 3'-end of each strand. Adapters were then ligated to both ends of the end repaired/dA tailed DNA fragments and amplified by ligation-mediated PCR (LM-PCR), followed by single strand separation and cyclization. Rolling circle

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

amplification was performed to produce DNA Nanoballs (DNBs). The qualified DNBs were loaded into patterned nanoarrays and pair-end reads were read through on the BGISEQ-500 platform. High-throughput sequencing was performed for each library to ensure that each sample met the average sequencing coverage requirement of 35x. Sequencing-derived raw image files were processed by BGISEQ-500 base-calling software with default parameters, and the sequence data of each individual was generated as paired-end reads. Raw data in FASTQ format was filtered and raw reads with low quality were removed. Data was aligned to the human reference genome (GRCh37/HG19) by Burrows-Wheeler Aligner (BWA) v0.7.12 <sup>12, 13</sup> and variant calling was performed by Genome Analysis Toolkit (v3.3.0)<sup>14</sup> with duplicate reads removed by Picard tools v1.118.15 The HaplotypeCaller of GATK was used to call both SNPs and InDels simultaneously via local de-novo assembly of haplotypes in a region showing signs of variation. <sup>16, 17</sup> Base quality scores were recalibrated using GATK BaseRecalibrator and SNPs recalibration was performed using GATK VariantRecalibrator function. 18, 19 CHIP somatic variant identification and validation Heterozygous missense, nonsense, InDel and splicing variants of one or two base pairs in coding regions of CHIP-associated genes including ASXL1, TET2, JAK2, and DNMT3A were identified by filtering data from vcf files according to: 1) genotype quality > 30; 2) minor allele frequency <1% in 1000 genome database; 3) minor allele frequency <1% in the cohort. Variant analysis in RNAseq data in blood, aorta, liver, skeletal muscle, subcutaneous fat, visceral abdominal fat, monocyte derived macrophages and macrophage derived foam cells from STARNET subjects was performed for identification and validation of somatic mutations identified via whole genome sequencing. Because bone marrow or hematopoietic cells that carry somatic mutations could present in leukocytes in whole blood, in atherosclerotic plaques in the diseased aorta, or in macrophages and foam cells isolated and differentiated from whole blood, variants that presented in at least one of these four tissues/cell types but not in any other tissues (liver, skeletal muscle, subcutaneous fat, visceral abdominal fat) were defined as somatic mutations.

#### RNA sequencing and data processing

The effects of CHIP mutations on gene expression were studied in macrophages and foam cells. After centrifugation of whole blood, the cell pellet was washed with 1x PBS and cells were plated. After 3-6 hours, the monocytes adhered to the plate and non-adherent erythrocytes and lymphocytes could be washed off during adhesion purification. The monocytes were subsequently cultured in human serum, stimulated and differentiated into macrophages over 48-72 hours. The transition to foam cells was achieved by treatment with oxidized low-density lipoprotein (LDL) cholesterol. Finally, the macrophages and foam cells were harvested and RNA was isolated.<sup>11</sup>

RNA library preparation was based on the Ribo-Zero library preparation method using Illumina TruSeq nonstranded mRNA kit. Samples were randomized to prevent batch effects. Sequencing was performed with paired-end reads of 100 base pairs on an Illumina HiSeq, and quality control was performed using FASTQC3. GENCODE was used to quantify the expression of genes and isoforms and mapped to the human genome using STAR4. The average coverage was >40 million reads per sample. Only samples with more than 1 million unambiguously assigned reads were used for further analysis.

#### Genetics, imputation and eQTL analysis

Genetic data were analyzed on a genome build 37 background using GenomeStudio (Illumina). After genetic sex confirmation, quality control was performed using PLINK v 2.05. Data were imputed using the HRC r1.1 2016 reference panel using minimac4. Cis- and transregulated expression quantitative trait loci (eQTLs) in macrophages were determined using R package matrix eQTL v.2.1.1. Adjustments were made for age, sex, BMI and the first five genetic principal components. Cis-regulatory SNPs within 1 megabase of the respective gene

were determined by a linear regression model (hg19 genomes). An FDR <5% was considered statistically significant.

# Differential gene expression and pathway analysis

Differences in gene expression between CHIP mutation carriers and controls were investigated using the R package limma. Covariates in the linear regression model were age, sex and BMI. Adjusted p-values <0.05 were considered statistically significant. Differentially expressed genes were analyzed for overrepresentation of genes from genome-wide association studies (GWAS) to CAD using PhenoScanner. Differentially expressed genes were analyzed by binomial test for enrichment of Gene Ontology (GO) terms and by Gene Set Enrichment Analysis (GSEA). The maximum size of a gene set in GSEA was set to 3,000. Bonferronicorrected p-values <0.05 were considered statistically significant.

# **Network and Key Driver Analysis**

Regulatory networks were reconstructed using GENIE3, based on a random forests ensemble method.<sup>20</sup> The network was enriched with transcription factors and cis-eQTL-regulated genes from macrophages as candidate regulators.<sup>21, 22</sup> Weighted key driver analysis (wKDA) was performed using mergeomics.<sup>23, 24</sup> Mergeomics allows disease-relevant processes to be mapped onto molecular interaction networks in order to identify hubs as potential key regulators. The network visualization was realized with Cytoscape v3.7.0.

#### Co-expression modules and association with clinical traits

Correlation patterns between gene expression were analyzed using R package Weighted Gene Co-expression Network Analysis (WGCNA) to construct correlation networks and identify co-expression modules. Correlations of gene expression with clinical traits were calculated using Spearman correlation. The association of co-expression modules with clinical traits was analyzed using Fisher's exact test to calculate the enrichment of the number of significantly correlated genes in each module.

# Results

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

# CHIP screening by deep DNA sequencing

In MISSION, a total of 540 individuals who died at an age between 40 to 98 years old (mean age 75.1 years) were found to have CAD at autopsy. These subjects were screened for CHIP mutations with a mean sequencing depth of 3,592-fold, with at least 1,000-fold per gene. A total of 253 individuals (46.9%) carried 445 individual CHIP mutations in whole blood. The prevalence of CHIP mutations increased with age (R=0.76; p<0.001), the mean age of mutation carriers was 78.3 years and 113 (44.7%) were female. 78 individuals carried at least one CHIP mutation with a VAF >10%, 130 individuals carried at least one CHIP mutation with a VAF >2% and 45 individuals were identified with clonal hematopoiesis with a VAF <2% (Supplemental Figure 1). The greatest burden of CHIP was found in an 85-year-old man who carried 6 unique mutations. Most somatic mutations were identified in DNMT3A (155 mutations), TET2 (152) and ASXL1 (32). Further, CHIP mutations were detected in BCOR, CBL, CALR, CBL, EZH2, GNAS, GNB1, IDH1, JAK2, KRAS, PPM1D, RAD21, SETBP1, SF3B1, SMC1A, SMC3, SRSF2, TP53, U2AF1 and ZRSR2 (Supplemental Table 1). The presence of CHIP mutations in cardiovascular tissues was studied on DNA level in a subset of 25 confirmed CHIP mutation carriers. Specifically, we looked for respective mutations in atherosclerosis-affected coronary and carotid arteries, and myocardium of the left ventricle. Samples with VAF between 0.5% and 30.0% were analyzed. 18 identical CHIP mutations (i.e. in 72.0% of cases) were identified in at least one corresponding tissue, whereas no de novo mutation was detected on tissue level - serving as internal quality control. In 13 (52.0%) atherosclerosis-affected samples of the proximal left anterior descending (LAD) coronary artery CHIP mutations were retrieved: DNMT3A (5 mutations), TET2 (4), ASXL1 (1), CBL (1), PPM1D (1), and SMC3 (1). In atherosclerosis-affected carotid artery samples 10 mutations in DNMT3A (6 mutations), TET2 (3) and PPM1D (1) were identified, as well as 4 in the myocardium of the left ventricle of atherosclerosis-affected individuals in DNMT3A (1), TET2

(2) and *SMC3* (1). In general, leukocytes are the only DNA-containing cells in whole blood. In arterial tissue, various cells - e.g. smooth muscle cells, endothelial cells, leukocytes - carry DNA. Given the low proportion of leukocytes in atherosclerotic arterial tissue, an enrichment of CHIP-affected leukocytes - as identified for PPM1D - is likely in plaques (<u>Table 1</u>, Supplemental Figure 2).

# Visualization of specific CHIP mutations

To further detect and visualize specific point mutations of interest on RNA level in single cells custom made mutaFISH<sup>TM</sup> probes (Abnova, Taiwan) were designed.<sup>25, 26</sup> The targeted *DNMT3A* mutations c.2245T>C and c.2333G>T, initially identified in whole blood of CAD patients, were identified in leukocytes of the corresponding mutation carriers in human atherosclerotic plaque (Figure 2). For optimal orientation, all arterial samples were also stained for hematoxylin and eosin (HE) and Elastin van Gieson (EvG) (Supplemental Figure 3). Further, staining for CD68 revealed that CHIP-affected leukocytes in these cases could be identified as macrophages (Supplemental Figure 4). CHIP-mutated macrophages were mainly identified in the shoulder regions of advanced and inflammation rich plaques of human coronary and carotid samples (Figure 2, Supplemental Figure 4+5).

# **CHIP screening by WGS**

The 941 patients of the STARNET study undergoing open heart surgery were younger (65.9 years) and WGS sequencing had a lower depth (35-fold) than deep-DNAseq carried out in MISSION.<sup>11</sup> Overall, 159 specific CHIP mutations in the genes *ASXL1*, *DNMT3A*, *JAK2* or *TET2* were identified in 134 (14.2%) individuals in STARNET (**Supplemental Table 2**). Mean age of these CHIP mutation carriers was 67.1 years and 27 (17.0%) were female. 51 CHIP mutations could be confidentially replicated on RNA level in at least one tissue. Variant analysis in RNAseq data confirmed the CHIP mutations at the RNA level in whole blood (43 mutations), monocyte derived cultured macrophages (10 mutations) and cultured macrophage derived foam cells (5), as well as in atherosclerosis-affected aortic tissue (18) of CAD patients.

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

pathways

(GO:0019814,

GO:0003823.

GO:0006959,

GO:0006958,

CHIP in macrophages To study the effects of CHIP mutations on gene expression in macrophages we grouped individuals carrying TET2 and ASXL1 mutations and compared these to age- and sex-matched non-mutation carriers (controls). Most macrophages (>80%) belonged to the M0 subtype. Differential gene expression analysis of TET2-mutated macrophages Mean age of TET2 CHIP mutation carriers (n=3; c.6819G>T; c.6834C>T and c.7698T>C) and matched controls (n=21) showed no significant difference (60.3±12.0 vs 61.8±8.2 years). Detailed information on patient characteristics can be found in **Supplemental Table 3**. In total, 1,523 genes were differentially expressed in *TET2* mutation carriers compared to controls. 1,098 genes were upregulated and 425 genes were downregulated in CHIP mutation carriers. Top upregulated genes were LINC01882, IGKV3-15, IGHG2 and IGHA1, top downregulated genes were BMS1P10 and ZCCHC4 (padi.<0.05). GO analysis revealed as top enriched GO terms T cell receptor complex (GO:0042101), opsonization (GO:0008228) and immune response by circulating immunoglobulin (GO:0002455). In general, immune system and inflammation associated pathways were upregulated (Figure 3). Weighted Gene Co-expression Network Analysis (WGCNA) was used to establish coexpression modules based on macrophage RNAseg data from STARNET, to identify functional relations between genes, and based on genetic regulatory networks (GRN) to identify key driver genes. A total of 23 modules were generated from 10,267 transcripts with module sizes ranging between 36 to 2473 genes using the complete macrophage RNAseg data from STARNET. The gene functions of the co-expression modules were analyzed using GO terms. TET2 mutations in macrophages led to significant perturbation in the darkgreen module (p<0.001), which consists of 38 genes and is primarily involved in immune system related

GO:0002455.

GO:0006956, GO:0002768, GO:0002764, GO:0016064, GO:0019724; all p<0.001). Most relevant key driver genes in this module were *BACH2*, *BANK1*, *BLK*, *FCRL3*, *MS4A1* and *PAX5*. Significant associations were identified for the presence of severity and complexity of CAD based on coronary angiograms, measured by SYNTAX score (Figure 3).

# Differential gene expression analysis of ASXL1-mutated macrophages

After matching, mean age of ASXL1 CHIP mutation carriers (n=3; c.2331C>T; c.4890A>G and c.5137G>A) and controls (n=27) showed no significant difference (67.3±5.5 vs 67.3±5.6 years). Detailed information on patient characteristics can be found in Supplemental Table 4. In macrophages of ASXL1 CHIP mutation carriers 1,222 genes were differentially expressed compared to controls. 665 genes were upregulated and 557 genes were downregulated in CHIP mutation carriers. Top upregulated genes were HLA-DQB2, ASNS and SLC25A16, top downregulated genes were NPIPB2, HNRNPH1 and POLA2 (padj.<0.05). GO analysis revealed intracellular anatomical structure (GO:0005622), RNA binding (GO:0003723) and heterocyclic compound binding (GO:1901363) as top enriched terms. ASXL1 mutations led to upregulation of cell cycle and metabolic process associated pathways (Figure 4). ASXL1 mutations in macrophages led to significant perturbation in the black module (p<0.001), which consists of 468 genes and is involved in the intracellular translation of RNA into proteins (GO:0022626, GO:0006614, GO:0019083, GO:0006613, GO:0045047, GO:0006413, GO:0072599, GO:0000184, GO:0019080, GO:0070972; all p<0.001). Most relevant key driver genes in the black module were ANAPC16, CZIB, RPL7A, RPL14 and SNHG6. The black module was significantly associated with cardiometabolic relevant traits including low-density lipoprotein (LDL) and total cholesterol plasma levels, blood glucose and BMI, inflammation measured by plasma C-reactive protein (CRP) levels, and with the presence and complexity of coronary lesions (Figure 4).

#### Discussion

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

To further explore the role of CHIP mutations in CAD, we carried out large-scale, targeted deep-sequencing of genes prone to cause clonal hematopoiesis in MISSION, one of the largest postmortem biobanks focusing on cardiovascular disease. We found at least one characteristic mutation in about 46% of individuals who died with CAD at an average age of 78 years, highlighting that CHIP mutations were significantly more common in CAD patients than previously reported for subjects with unknown CAD status.<sup>2, 5, 27, 28</sup> In about 70% of affected individuals, the same mutation could be detected within cardiovascular tissues, either in DNA or – in case of coding variants – around one third in RNA. Albeit the cellular composition is different in blood and various tissues, a similar percentage of cells carrying CHIP mutations was found in respective samples. Exemplary visualization of two different DNMT3A mutations was achieved within macrophages residing in atherosclerotic human coronary and carotid arteries by in situ fluorescent staining. CHIP mutations, which are thought to promote the development and progression of ischemic heart failure, 6, 29, 30 were also detected in left ventricular myocardial samples of CAD patients. The implications of CHIP mutations were then investigated using the STARNET datasets, focusing on CAD patients undergoing open heart surgery (average age 67 years). 11, 31 Based on whole-genome sequencing and RNAseg data - carried out at a lower depth than the targeted deep-sequencing in MISSION - CHIP mutations were found in about 14% of CAD patients, who most likely represented higher VAFs in affected individuals. Mutations were also detected in aortic samples affected by atherosclerosis, monocyte-derived macrophages, and foam cells. This allowed us to further study the implications of CHIP mutations with respect to clinical presentations and RNA expression patterns. RNA sequencing revealed large numbers of differentially expressed genes in macrophages of CHIP mutation carriers – as compared to patients free of these mutations. Interestingly, patterns of gene expression also differed between those having mutations in TET2 and ASXL1, i.e. two of the most prominent CHIP mutations.

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

Patients carrying TET2-mutations had a higher CAD burden and – as measured by SYNTAX score – more complex CAD. Macrophages generated in vitro by transformation of monocytes from these patients revealed multiple differentially expressed genes. Enrichment analysis revealed upregulation of immune system and inflammation associated pathways. Specifically, TET2 mutations related to perturbation of a small atherosclerosis relevant macrophage gene expression network with most relevant key driver genes being BACH2, BANK1, BLK, FCRL3, MS4A1 and PAX5 mainly involved in immune response, cell migration and leukocyte differentiation. ASXL1 CHIP mutation carriers revealed upregulation of cardiometabolic relevant traits including low-density lipoprotein (LDL) cholesterol plasma levels, inflammation measured by plasma C-reactive protein (CRP) levels, and – like TET2 mutations – a higher prevalence and complexity of CAD. In macrophages, ASXL1 CHIP mutations revealed differentially expressed genes, of note inflammasome related genes were upregulated. Enrichment analysis of differentially expressed genes revealed that ASXL1 mutations related to perturbations of pathways associated with cell cycle and metabolic processes. Top key drivers affected by CHIP mutations were ANAPC16, CZIB, RPL7A, RPL14 and SNHG6 mainly involved in regulation of metabolic processes, ubiquitination and protein synthesis. Given the relevance of inflammation and cardiovascular conditions that have been associated with CHIP, there appears to be an opportunity to treat selected patients with specific antiinflammatory strategies, 32-34 for example, by targeting the NLRP3 inflammasome, IL-1\beta or IL-6 with agents like canakinumab (monoclonal antibody against IL-1\beta), 35 anakinra (an IL-1\beta receptor antagonist), 36-39 tocilizumab (monoclonal antibody against the IL-6 receptor), 40, 41 ziltevekimab (anti-*IL-6* ligand monoclonal antibody), 42 or colchicine. 43-45 Interestingly, an exploratory retrospective analysis of the CANTOS trial that studied the effects of canakinumab in patients with an acute coronary syndrome suggested increased inflammatory activation and more cardiovascular events, as well as specific treatment benefits in carriers of CHIPmutations. However, the value of this analysis is limited as only 40% of the initial CANTOS

population was screened for CHIP mutations such that the overall number of CHIP mutation carriers was low.<sup>46</sup> Our study supports the concept that specific CHIP mutations might identify subgroups of patients with explicit alterations in gene expression in various cardiovascular relevant tissues – mainly stimulating pro-inflammatory mechanisms – which might be relevant in the future for directing specific treatments to these individuals.

# Limitations

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

Our study has several limitations. Firstly, as we have no longitudinal data, it is unclear how long individual CHIP mutations have been present. CHIP mutations are acquired over decades and their related risks may grow over time. However, the exact time of acquisition of CHIP mutations is difficult to determine and unknown in most cases. Secondly, the limited depth of WGS in STARNET and the focused CHIP screening panel in MISSION may have left mutation carriers undetected. Overlooking CHIP mutation carriers in STARNET may have impaired our sensitivity to discriminate their related effects on clinical and transcriptional characteristics. Thirdly, different DNA sequencing platforms have different levels of coverage, specificity and sensitivity, making it difficult to compare results from different platforms. Standardization of sequencing methods and analysis pipelines would be desirable to ensure comparability of results and improve the accuracy of CHIP screening in the future. Fourth, the relevance of respective mutations and the quantitative burden of VAFs need further clarification. The VAF of CHIP mutations is an essential factor in determining their biological significance, but there is a limited knowledge of optimal VAF 'cut-offs' for individual CHIP mutations. Yet, high VAF has been associated with an increased risk of cardiovascular events. In chronic ischemic heart failure (CHF), individual clone size thresholds of less than 2% in DNMT3A and TET2 have already been associated with worse outcomes.<sup>29</sup> It remains to be clarified which VAF threshold is relevant for individual CHIP mutations and specific phenotypes, and whether these could serve as novel biomarkers or support treatment decisions. Fifth, the relevance of respective mutations in one or the other gene, including the additive effects of multiple mutations needs further investigation. An essential key for future personalized therapy approaches will be to

validate these CHIP related outcomes in well-powered, prospective RCTs. Finally, the local effects of individual CHIP-mutated macrophages residing within cardiovascular tissues needs spatial investigation.

#### Conclusions

Our data highlight that blood derived circulating CHIP-affected leukocytes have the potential to invade human atherosclerotic lesions in coronary and carotid arteries, aorta, and heart muscle. We visualized CHIP-mutated leukocytes with single cell resolution in human atherosclerotic plaques and staining confirmed these leukocytes as CD68+ macrophages. Since these acquired CHIP mutations originate from hematopoietic stem or progenitor cells in the bone marrow and were identified in whole blood, the visualized CHIP mutations cannot originate from resident arterial macrophages. Further, RNA sequencing identified CHIP specific signatures in macrophages, novel key regulators and associations with clinical traits like burden and complexity of CAD (Figure 1). Future studies are needed to further characterize underlying molecular mechanisms by which individual mutations contribute to CVDs and whether targeting specific pathways may be valuable for precision medicine in patients carrying mutations encoding for CHIP.

# **Novelty and Significance**

# What is known? (2-3 bullet points)

- CHIP represents an independent risk factor for the onset and progression of cardiovascular diseases and death
- CHIP mutations are associated with inflammatory activation of circulating monocytes and T-cells
  - Individual CHIP mutations could be important as biomarkers in the future and help identify high-risk patients suitable for anti-inflammatory therapy

#### What new information does this article contribute? (max. 200 words)

Our work provides insights on three open questions in the field. Firstly, we provide higher estimates of the proportion of CAD patients affected by CHIP mutations, if these are studied by focused deep-sequencing in whole blood. Next, we show that CHIP-mutated leukocytes have the potential to invade human plaques and thereby contribute locally to atherosclerosis. Specifically, we visualized macrophages at single cell resolution by a specific *DNMT3A* CHIP mutations probe in coronary plaques. We also identified blood derived CHIP mutations in human coronary and carotid arteries and heart muscle on DNA level. Additionally, we describe previously unknown key-regulatory genes and pro-atherosclerotic alterations at the RNA level of CHIP mutated macrophages. Importantly, different CHIP mutations appear to affect different pathways, networks and modules, which nevertheless all have relevance for CAD progression. These novel results (Figure 1) appear to be of relevance for future personalized medicine approaches specifically designed for CHIP mutation carriers.

# **Acknowledgments**

M.v.S drafted the manuscript, designed and coordinated the study. J.K., M.G. and C.B. provided human cardiovascular tissues in MISSION. M.v.S, S.B., J.F., D.B. and L.O. performed the CHIP screening in MISSION. S.B. performed the mutaFISH<sup>TM</sup> experiment. A.M., K.H., A.R., J.C.K. and J.L.M.B. contributed data from STARNET. Y.W., C.J.H., S.K.B.G., M.M., H.G., K.K., A.S., C.M., N.L., J.L.M.B. and H.S. provided relevant intellectual input within the Leducq PlaqOmics Consortium. B.V., T.K., Z.C., A.M., H.B.S. and L.M. were involved RNAseq analyses. J.S.H., F.B. and W.K. provided relevant intellectual input regarding hematological aspects and biomarkers. A.M.Z. and S.D. supported within the joint DZHK CHIP moonshot project. All authors critically reviewed the manuscript and agreed with the final version of the manuscript, written by M.v.S. J.L.M.B. and H.S.. Special thanks for scientific support to the Munich Leukemia Laboratory (MLL), Germany. Illustrations contain image material available at Servier Medical Art under a creative commons attribution 3.0 unported license.

# Sources of Funding

This study was funded by the German Center for Cardiovascular Research (DZHK), Berlin, Germany, (DZHK81X2200145 and DZHK-81X2600520). M.v.S. is supported by an excellence grant of the German Center for Cardiovascular Research (DZHK-81X3600506), the German Heart Foundation (Deutsche Herzstiftung e.V.), and a Junior Research Group Cardiovascular Diseases Grant of the CORONA Foundation (S199/10085/2021). M.v.S., Y.W., C.J.H., S.K.B.G., M.M., H.G., K.K., A.S. and A.A. are supported by a Leducq PlaqOmics Junior Investigator Grant. This work was further supported by grants from the Fondation Leducq (PlaqOmics), the Bavarian State Ministry of Health and Care through the research project DigiMed Bayern (www.digimed-bayern.de), the Bavarian State Ministry of Science and the Arts through the research project Deutsches Herzzentrum München and Munich School of Robotics and Machine learning Joint Research Center, the German Federal Ministry of Education and Research within the framework of European Research Area Network on Cardiovascular

Disease. J.C.K. acknowledges research support from the National Institutes of Health (R01HL148167), New South Wales health grant RG194194, the Bourne Foundation and Agilent. J.L.M.B. acknowledges support from the Swedish Research Council (2018-02529 and 2022-00734), the Swedish Heart Lung Foundation (2017-0265 and 2020-0207), the Leducq Foundation AteroGen (22CVD04) and PlaqOmics (18CVD02) consortia; the National Institute of Health-National Heart Lung Blood Institute (NIH/NHLBI, R01HL164577; R01HL148167; R01HL148239, R01HL166428, and R01HL168174), American Heart Association Transformational Project Award 19TPA34910021, and from the CMD AMP fNIH program.

# **Disclosures**

497 None.

#### References

- 499 1. Genovese G, Kahler AK, Handsaker RE, Lindberg J, Rose SA, Bakhoum SF,
- 500 Chambert K, Mick E, Neale BM, Fromer M, Purcell SM, Svantesson O, Landen M, Hoglund
- M, Lehmann S, Gabriel SB, Moran JL, Lander ES, Sullivan PF, Sklar P, Gronberg H,
- Hultman CM and McCarroll SA. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. *N Engl J Med.* 2014;371:2477-87.
- 504 2. Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman PV, Mar BG, Lindsley RC,
- Mermel CH, Burtt N, Chavez A, Higgins JM, Moltchanov V, Kuo FC, Kluk MJ, Henderson B,
- 506 Kinnunen L, Koistinen HA, Ladenvall C, Getz G, Correa A, Banahan BF, Gabriel S,
- Kathiresan S, Stringham HM, McCarthy MI, Boehnke M, Tuomilehto J, Haiman C, Groop L,
- 508 Atzmon G, Wilson JG, Neuberg D, Altshuler D and Ebert BL. Age-related clonal
- hematopoiesis associated with adverse outcomes. *N Engl J Med*. 2014;371:2488-98.
- 510 3. Young AL, Challen GA, Birmann BM and Druley TE. Clonal haematopoiesis
- harbouring AML-associated mutations is ubiquitous in healthy adults. *Nat Commun.*
- 512 2016;7:12484.
- 513 4. Hecker JS, Hartmann L, Riviere J, Buck MC, van der Garde M, Rothenberg-Thurley
- M, Fischer L, Winter S, Ksienzyk B, Ziemann F, Solovey M, Rauner M, Tsourdi E, Sockel K,
- 515 Schneider M, Kubasch AS, Nolde M, Hausmann D, Paulus AC, Lutzner J, Roth A,
- 516 Bassermann F, Spiekermann K, Marr C, Hofbauer LC, Platzbecker U, Metzeler KH and
- 517 Gotze KS. CHIP and hips: clonal hematopoiesis is common in patients undergoing hip
- arthroplasty and is associated with autoimmune disease. *Blood*. 2021;138:1727-1732.
- 519 5. Jaiswal S, Natarajan P, Silver AJ, Gibson CJ, Bick AG, Shvartz E, McConkey M,
- Gupta N, Gabriel S, Ardissino D, Baber U, Mehran R, Fuster V, Danesh J, Frossard P,
- Saleheen D, Melander O, Sukhova GK, Neuberg D, Libby P, Kathiresan S and Ebert BL.
- Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease. *N Engl J Med.*
- 523 2017;377:111-121.
- 524 6. Dorsheimer L, Assmus B, Rasper T, Ortmann CA, Ecke A, Abou-El-Ardat K, Schmid
- T, Brune B, Wagner S, Serve H, Hoffmann J, Seeger F, Dimmeler S, Zeiher AM and Rieger
- MA. Association of Mutations Contributing to Clonal Hematopoiesis With Prognosis in
- 527 Chronic Ischemic Heart Failure. *JAMA Cardiol.* 2019;4:25-33.
- 528 7. Bhattacharya R, Zekavat SM, Haessler J, Fornage M, Raffield L, Uddin MM, Bick AG,
- Niroula A, Yu B, Gibson C, Griffin G, Morrison AC, Psaty BM, Longstreth WT, Bis JC, Rich
- SS, Rotter JI, Tracy RP, Correa A, Seshadri S, Johnson A, Collins JM, Hayden KM, Madsen
- TE, Ballantyne CM, Jaiswal S, Ebert BL, Kooperberg C, Manson JE, Whitsel EA, Program
- NT-OfPM, Natarajan P and Reiner AP. Clonal Hematopoiesis Is Associated With Higher Risk of Stroke. *Stroke*. 2022;53:788-797.
- 534 8. Gumuser ED, Schuermans A, Cho SMJ, Sporn ZA, Uddin MM, Paruchuri K, Nakao T,
- Yu Z, Haidermota S, Hornsby W, Weeks LD, Niroula A, Jaiswal S, Libby P, Ebert BL, Bick
- 536 AG, Natarajan P and Honigberg MC. Clonal Hematopoiesis of Indeterminate Potential
- 537 Predicts Adverse Outcomes in Patients With Atherosclerotic Cardiovascular Disease. *J Am Coll Cardiol.* 2023;81:1996-2009.
- 539 9. Fuster JJ, MacLauchlan S, Zuriaga MA, Polackal MN, Ostriker AC, Chakraborty R,
- Wu CL, Sano S, Muralidharan S, Rius C, Vuong J, Jacob S, Muralidhar V, Robertson AA,
- Cooper MA, Andres V, Hirschi KK, Martin KA and Walsh K. Clonal hematopoiesis associated
- 542 with TET2 deficiency accelerates atherosclerosis development in mice. Science.
- 543 2017;355:842-847.
- 544 10. Libby P and Ebert BL. CHIP (Clonal Hematopoiesis of Indeterminate Potential):
- Potent and Newly Recognized Contributor to Cardiovascular Risk. *Circulation*. 2018;138:666-668.
- 11. Koplev S, Seldin S, Sukhavasi K, Ermel R, Pang S, Zeng L, Bankier S, Di Narzo A,
- 548 Cheng H, Meda V, Ma A, Talukdar H, Cohain A, Amadori L, Argmann C, Houten S, Franzén
- O, Mocci G, Meelu O, Ishikawa K, Whatling C, Jain A, Jain R, Gan L, Giannarelli C, Roussos
- 550 P, Hao K, Schunkert H, Michoel T, Ruusalepp A, Schadt E, Kovacic J, Lusis A and
- 551 Björkegren J. A mechanistic framework for cardiometabolic and coronary artery diseases.
- 552 Nature Cardiovascular Research. 2022;1:85–100.

- 553 12. Li H and Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. *Bioinformatics*. 2009;25:1754-60.
- 555 13. Li H and Durbin R. Fast and accurate long-read alignment with Burrows-Wheeler transform. *Bioinformatics*. 2010;26:589-95.
- 557 14. Nowak J, Koscinska K, Mika-Witkowska R, Rogatko-Koros M, Mizia S, Jaskula E,
- Polak M, Mordak-Domagala M, Lange J, Gronkowska A, Jedrzejczak WW, Kyrcz-Krzemien
- 559 S, Markiewicz M, Dzierzak-Mietla M, Tomaszewska A, Nasilowska-Adamska B, Szczepinski
- A, Halaburda K, Hellmann A, Komarnicki M, Gil L, Czyz A, Wachowiak J, Baranska M,
- Kowalczyk J, Drabko K, Gozdzik J, Wysoczanska B, Bogunia-Kubik K, Graczyk-Pol E,
- Witkowska A, Marosz-Rudnicka A, Nestorowicz K, Dziopa J, Szlendak U, Warzocha K and
- Lange AA. Donor NK cell licensing in control of malignancy in hematopoietic stem cell
- transplant recipients. *Am J Hematol.* 2014;89:E176-83.
- 565 15. Broadinstitute. Picard. 2022;2022:Picard v1.118.
- 16. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, Garimella
- 567 K, Altshuler D, Gabriel S, Daly M and DePristo MA. The Genome Analysis Toolkit: a
- 568 MapReduce framework for analyzing next-generation DNA sequencing data. *Genome Res.* 2010;20:1297-303.
- 570 17. Poplin R, Ruano-Rubio V, DePristo MA, Fennell TJ, Carneiro MO, Van der Auwera
- 571 GA, Kling DE, Gauthier LD, Levy-Moonshine A, Roazen D, Shakir K, Thibault J, Chandran S,
- Whelan C, Lek M, Gabriel S, Daly MJ, Neale B, MacArthur DG and Banks E. Scaling
- accurate genetic variant discovery to tens of thousands of samples. *bioRxiv*. 2018:201178.
- 574 18. DePristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, Hartl C, Philippakis AA,
- 575 del Angel G, Rivas MA, Hanna M, McKenna A, Fennell TJ, Kernytsky AM, Sivachenko AY,
- 576 Cibulskis K, Gabriel SB, Altshuler D and Daly MJ. A framework for variation discovery and genotyping using next-generation DNA sequencing data. *Nat Genet*. 2011;43:491-8.
- 578 19. Van der Auwera GA, Carneiro MO, Hartl C, Poplin R, Del Angel G, Levy-Moonshine
- A, Jordan T, Shakir K, Roazen D, Thibault J, Banks E, Garimella KV, Altshuler D, Gabriel S
- and DePristo MA. From FastQ data to high confidence variant calls: the Genome Analysis
- Toolkit best practices pipeline. *Curr Protoc Bioinformatics*. 2013;43:11 10 1-11 10 33.

  Huynh-Thu VA and Geurts P. dynGENIE3: dynamical GENIE3 for the inference of
- 583 gene networks from time series expression data. *Sci Rep.* 2018;8:3384.
- 21. Lizio M, Harshbarger J, Shimoji H, Severin J, Kasukawa T, Sahin S, Abugessaisa I,
- Fukuda S, Hori F, Ishikawa-Kato S, Mungall CJ, Arner E, Baillie JK, Bertin N, Bono H, de
- Hoon M, Diehl AD, Dimont E, Freeman TC, Fujieda K, Hide W, Kaliyaperumal R, Katayama
- T, Lassmann T, Meehan TF, Nishikata K, Ono H, Rehli M, Sandelin A, Schultes EA, t Hoen
- PA, Tatum Z, Thompson M, Toyoda T, Wright DW, Daub CO, Itoh M, Carninci P,
- Hayashizaki Y, Forrest AR, Kawaji H and consortium F. Gateways to the FANTOM5
- 590 promoter level mammalian expression atlas. *Genome Biol.* 2015;16:22.
- 591 22. Abugessaisa I, Ramilowski JA, Lizio M, Severin J, Hasegawa A, Harshbarger J,
- Kondo A, Noguchi S, Yip CW, Ooi JLC, Tagami M, Hori F, Agrawal S, Hon CC, Cardon M,
- 593 Ikeda S, Ono H, Bono H, Kato M, Hashimoto K, Bonetti A, Kato M, Kobayashi N, Shin J, de
- Hoon M, Hayashizaki Y, Carninci P, Kawaji H and Kasukawa T. FANTOM enters 20th year:
- expansion of transcriptomic atlases and functional annotation of non-coding RNAs. *Nucleic Acids Res.* 2021;49:D892-D898.
- 597 23. Shu L, Zhao Y, Kurt Z, Byars SG, Tukiainen T, Kettunen J, Orozco LD, Pellegrini M,
- Lusis AJ, Ripatti S, Zhang B, Inouye M, Makinen VP and Yang X. Mergeomics:
- multidimensional data integration to identify pathogenic perturbations to biological systems. *BMC Genomics*. 2016;17:874.
- 601 24. Ding J, Blencowe M, Nghiem T, Ha SM, Chen YW, Li G and Yang X. Mergeomics 2.0:
- a web server for multi-omics data integration to elucidate disease networks and predict
- therapeutics. Nucleic Acids Res. 2021;49:W375-W387.
- 604 25. Larsson C, Grundberg I, Soderberg O and Nilsson M. In situ detection and
- genotyping of individual mRNA molecules. *Nat Methods*. 2010;7:395-7.
- 606 26. Larsson C, Koch J, Nygren A, Janssen G, Raap AK, Landegren U and Nilsson M. In
- 607 situ genotyping individual DNA molecules by target-primed rolling-circle amplification of
- 608 padlock probes. *Nat Methods*. 2004;1:227-32.

- 609 27. Yu Z, Fidler TP, Ruan Y, Vlasschaert C, Nakao T, Uddin MM, Mack T, Niroula A,
- 610 Heimlich JB, Zekavat SM, Gibson CJ, Griffin GK, Wang Y, Peloso GM, Heard-Costa N, Levy
- D, Vasan RS, Aguet F, Ardlie K, Taylor KD, Rich SS, Rotter JI, Libby P, Jaiswal S, Ebert BL,
- 612 Bick AG, Tall AR and Natarajan P. Genetic modification of inflammation and clonal
- 613 hematopoiesis-associated coronary artery disease. *medRxiv*. 2022:2022.12.08.22283237.
- 614 28. Jaiswal S and Libby P. Clonal haematopoiesis: connecting ageing and inflammation
- in cardiovascular disease. *Nat Rev Cardiol.* 2020;17:137-144.
- 616 29. Assmus B, Cremer S, Kirschbaum K, Culmann D, Kiefer K, Dorsheimer L, Rasper T,
- 617 Abou-El-Ardat K, Herrmann E, Berkowitsch A, Hoffmann J, Seeger F, Mas-Peiro S, Rieger
- 618 MA, Dimmeler S and Zeiher AM. Clonal haematopoiesis in chronic ischaemic heart failure:
- prognostic role of clone size for DNMT3A- and TET2-driver gene mutations. *Eur Heart J.*
- 620 2021;42:257-265.
- 621 30. Pascual-Figal DA, Bayes-Genis A, Diez-Diez M, Hernandez-Vicente A, Vazquez-
- Andres D, de la Barrera J, Vazquez E, Quintas A, Zuriaga MA, Asensio-Lopez MC, Dopazo
- A, Sanchez-Cabo F and Fuster JJ. Clonal Hematopoiesis and Risk of Progression of Heart
- Failure With Reduced Left Ventricular Ejection Fraction. J Am Coll Cardiol. 2021;77:1747-
- 625 1759.
- 626 31. Franzen O, Ermel R, Cohain A, Akers NK, Di Narzo A, Talukdar HA, Foroughi-Asl H,
- 627 Giambartolomei C, Fullard JF, Sukhavasi K, Koks S, Gan LM, Giannarelli C, Kovacic JC,
- Betsholtz C, Losic B, Michoel T, Hao K, Roussos P, Skogsberg J, Ruusalepp A, Schadt EE
- and Bjorkegren JL. Cardiometabolic risk loci share downstream cis- and trans-gene
- regulation across tissues and diseases. *Science*. 2016;353:827-30.
- 32. Tall AR and Bornfeldt KE. Inflammasomes and Atherosclerosis: a Mixed Picture. *Circ*
- 632 Res. 2023;132:1505-1520.
- 633 33. Hettwer J, Hinterdobler J, Miritsch B, Deutsch MA, Li X, Mauersberger C, Moggio A,
- Braster Q, Gram H, Robertson AAB, Cooper MA, Gross O, Krane M, Weber C, Koenig W,
- Soehnlein O, Adamstein NH, Ridker P, Schunkert H, Libby P, Kessler T and Sager HB.
- 636 Interleukin-1beta suppression dampens inflammatory leucocyte production and uptake in
- 637 atherosclerosis. Cardiovasc Res. 2022;118:2778-2791.
- 638 34. Abbate A, Toldo S, Marchetti C, Kron J, Van Tassell BW and Dinarello CA.
- Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease. *Circ Res.* 2020;126:1260-1280.
- 641 35. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C,
- Fonseca F, Nicolau J, Koenig W, Anker SD, Kastelein JJP, Cornel JH, Pais P, Pella D,
- 643 Genest J, Cifkova R, Lorenzatti A, Forster T, Kobalava Z, Vida-Simiti L, Flather M,
- 644 Shimokawa H, Ogawa H, Dellborg M, Rossi PRF, Troquay RPT, Libby P, Glynn RJ and
- 645 Group CT. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl
- 646 J Med. 2017;377:1119-1131.
- 647 36. Abbate A, Trankle CR, Buckley LF, Lipinski MJ, Appleton D, Kadariya D, Canada JM,
- 648 Carbone S, Roberts CS, Abouzaki N, Melchior R, Christopher S, Turlington J, Mueller G,
- Garnett J, Thomas C, Markley R, Wohlford GF, Puckett L, Medina de Chazal H, Chiabrando
- JG, Bressi E, Del Buono MG, Schatz A, Vo C, Dixon DL, Biondi-Zoccai GG, Kontos MC and
- Van Tassell BW. Interleukin-1 Blockade Inhibits the Acute Inflammatory Response in
- 652 Patients With ST-Segment-Elevation Myocardial Infarction. J Am Heart Assoc.
- 653 2020;9:e014941.
- 654 37. Buckley LF and Abbate A. Interleukin-1 blockade in cardiovascular diseases: a
- 655 clinical update. Eur Heart J. 2018;39:2063-2069.
- 656 38. Dragoljevic D, Lee MKS, Louis C, Shihata W, Kraakman MJ, Hansen J, Masters SL,
- 657 Hanaoka BY, Nagareddy PR, Lancaster GI, Wicks IP and Murphy AJ. Inhibition of
- 658 interleukin-1beta signalling promotes atherosclerotic lesion remodelling in mice with
- inflammatory arthritis. *Clin Transl Immunology*. 2020;9:e1206.
- 660 39. Ku EJ, Kim BR, Lee JI, Lee YK, Oh TJ, Jang HC and Choi SH. The Anti-
- Atherosclerosis Effect of Anakinra, a Recombinant Human Interleukin-1 Receptor Antagonist,
- in Apolipoprotein E Knockout Mice. Int J Mol Sci. 2022;23.

- 663 40. Hartman J and Frishman WH. Inflammation and atherosclerosis: a review of the role of interleukin-6 in the development of atherosclerosis and the potential for targeted drug
- 665 therapy. Cardiol Rev. 2014;22:147-51.
- 666 41. Poznyak AV, Bharadwaj D, Prasad G, Grechko AV, Sazonova MA and Orekhov AN.
- Anti-Inflammatory Therapy for Atherosclerosis: Focusing on Cytokines. *Int J Mol Sci.* 2021;22.
- 669 42. Ridker PM, Devalaraja M, Baeres FMM, Engelmann MDM, Hovingh GK, Ivkovic M, Lo
- L, Kling D, Pergola P, Raj D, Libby P, Davidson M and Investigators R. IL-6 inhibition with
- ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised,
- 672 placebo-controlled, phase 2 trial. *Lancet*. 2021;397:2060-2069.
- 43. Tardif JC, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP, Pinto FJ, Ibrahim
- R, Gamra H, Kiwan GS, Berry C, Lopez-Sendon J, Ostadal P, Koenig W, Angoulvant D,
- 675 Gregoire JC, Lavoie MA, Dube MP, Rhainds D, Provencher M, Blondeau L, Orfanos A,
- 676 L'Allier PL, Guertin MC and Roubille F. Efficacy and Safety of Low-Dose Colchicine after
- 677 Myocardial Infarction. *N Engl J Med*. 2019;381:2497-2505.
- 678 44. Nidorf SM, Fiolet ATL, Mosterd A, Eikelboom JW, Schut A, Opstal TSJ, The SHK, Xu
- 679 XF, Ireland MA, Lenderink T, Latchem D, Hoogslag P, Jerzewski A, Nierop P, Whelan A,
- Hendriks R, Swart H, Schaap J, Kuijper AFM, van Hessen MWJ, Saklani P, Tan I, Thompson
- AG, Morton A, Judkins C, Bax WA, Dirksen M, Alings M, Hankey GJ, Budgeon CA, Tijssen
- JGP, Cornel JH, Thompson PL and LoDoCo2 Trial I. Colchicine in Patients with Chronic
- 683 Coronary Disease. *N Engl J Med*. 2020;383:1838-1847.
- 684 45. Opstal TSJ, van Broekhoven A, Fiolet ATL, Mosterd A, Eikelboom JW, Nidorf SM,
- Thompson PL, Budgeon CA, Bartels L, de Nooijer R, Bax WA, Tijssen JGP, El Messaoudi S
- and Cornel JH. Long-Term Efficacy of Colchicine in Patients With Chronic Coronary Disease:
- 687 Insights From LoDoCo2. *Circulation*. 2022;145:626-628.
- 688 46. Svensson EC, Madar A, Campbell CD, He Y, Sultan M, Healey ML, Xu H, D'Aco K,
- Fernandez A, Wache-Mainier C, Libby P, Ridker PM, Beste MT and Basson CT. TET2-
- 690 Driven Clonal Hematopoiesis and Response to Canakinumab: An Exploratory Analysis of the
- 691 CANTOS Randomized Clinical Trial. JAMA Cardiol. 2022;7:521-528.

**Tables** 692 693 Table 1 - deep-DNAseq identifies CHIP mutations in atherosclerotic plaques and left 694 ventricular myocardium 695 696 **Figures** 697 Figure 1 – Central illustration highlighting most relevant novel findings Figure 2 - mutaFISH™ visualizes CHIP-mutated leukocytes in human plaques 698 699 Figure 3 – RNAseq of macrophages (TET2-CHIP vs non mutation carriers) 700 Figure 4 – RNAseq of macrophages (ASXL1-CHIP vs non mutation carriers) 701 702 Supplement 703 **Supplemental Table 1** – List of CHIP mutations in MISSION 704 Supplemental Table 2 – List of CHIP mutations in STARNET 705 **Supplemental Table 3** – STARNET patient characteristics TET2 macrophages 706 **Supplemental Table 4** – STARNET patient characteristics ASXL1 macrophages 707 Supplemental Figure 1 – VAF and distribution of CHIP mutations in MISSION 708 **Supplemental Figure 2** – Deep-DNAseq identifies CHIP mutations in atherosclerotic 709 coronary and carotid samples, and left ventricular myocardium 710 **Supplemental Figure 3** – Overview plaque of interest – different stainings 711 Supplemental Figure 4 – Visualization of CD68<sup>+</sup> CHIP mutated macrophage 712 **Supplemental Figure 5** – DNMT3A CHIP mutation (c.2245C>T) in human atherosclerotic 713 plaque 714 **Protocol** – adapted mutaFISH<sup>™</sup> protocol

**Table 1 –** This study provides evidence that CHIP-mutated leukocytes have the potential to invade human atherosclerotic plaques in coronary and carotid arteries, and heart muscle from peripheral blood. Out of 25 unique CHIP mutations (identified in whole blood), 18 mutations (shown) were identified in at least one corresponding tissue of interest. Tissue sequencing of CHIP mutation carriers revealed that identical CHIP mutations were identified in the corresponding coronary artery (n=13), carotid artery (n=10) and left ventricular heart muscle (n=4) (right). Provided are mutations on DNA level and variant allele frequency (VAF) in %.

CHIP-affected gene	Whole Blood	Coronary	Carotid	Heart Muscle
(mutation)	(VAF in %)	(VAF in %)	(VAF in %)	(VAF in %)
<b>ASXL1</b> (c.1772dup)	5.2	1.2	0	0
<b>CBL</b> (c.1211G>A)	9.1	2.2	0	0
<b>DNMT3A</b> (c.1628G>C)	21.6	0	5.4	0
<b>DNMT3A</b> (c.976C>T)	20.5	0	2.4	0
<b>DNMT3A</b> (c.2333T>G)	6.5	2.5	0	0
<b>DNMT3A</b> (c.2245C>T)	5.6	1.5	0	1.5
<b>DNMT3A</b> (c.1726_1729delinsC)	22.6	5.9	5.8	0
<b>DNMT3A</b> (c.1969G>A)	5.3	1.0	1.1	0
<b>DNMT3A</b> (c.2204A>G)	11.3	0	2.5	0
<b>DNMT3A</b> (c.2104G>T)	11.8	1.4	2.7	0
<b>PPM1D</b> (c.1535del)	0.7	0	2.0	0
<b>PPM1D</b> (c.1535del)	0.9	1.8	0	0
<b>SMC3</b> (c.3598G>A)	6.0	1.1	0	1.0
<b>TET2</b> (c.2839C>T)	19.2	4.0	5.1	0
<b>TET2</b> (c.4193T>G)	6.4	2.1	2.1	0
<b>TET2</b> (c.1219del)	27.7	4.4	0	2.0
<b>TET2</b> (c.4546C>T)	29.7	5.1	0	2.6
<b>TET2</b> (c.5454_5458del)	9.8	0	2.1	0




Figure 1. Central illustration – important novel findings from this study. Left panel: Over 300 CHIP mutation carriers from the Munich cardlovaScular Studles biObaNk (MISSION) and the Stockholm-Tartu Atherosclerosis Reverse Networks Engineering Task (STARNET) studies were evaluated. Upper panel: In our study, we confirmed blood derived CHIP mutations in human atherosclerotic plaques of coronary artery, carotids and heart muscle on DNA level. Middle panel: For the first time we were able to visualize macrophages with specific *DNMT3A* CHIP mutations using mutaFISH™ at single cell resolution in human atherosclerotic plaques. Enrichment of CHIP mutated cells in human plaques was confirmed. Lower panel: Previously unknown pro-atherosclerotic alterations in gene expression of CHIP mutated macrophages at the level of regulatory key-drivers, pathways, networks, and modules with relevance for CAD progression were identified. ASXL1: ASXL Transcriptional Regulator 1; CAD: Coronar artery disease; CHIP: Clonal hematopoiesis of indeterminate potential; DNMT3A: DNA Methyltransferase 3 Alpha; HSC: hematopoietic stem cell; mutaFISH: mutation-specific Fluorescence In Situ Hybridization; TET2: Tet Methylcytosine Dioxygenase 2.




Figure 2 – CHIP-mutated cells have the potential to invade from the peripheral blood into human atherosclerotic lesions. mutaFISH™ allowed detection of single nucleotide exchanges at the RNA level in single cells. Staining for a specific DNMT3A mutation (mut) and wild type (wt) at the RNA level was performed *in situ* in advanced atherosclerotic plaques of human FFPE coronary tissue. **Left panel**: merged overview of an advanced atherosclerotic plaque. Red boxes highlight areas of interest enlarged in the following panels. **Middle panel**: CHIP-affected leukocytes were identified in the inflammatory shoulder regions of human atherosclerotic plaque (white arrow). **Right panel**: The DNMTA3 mutation c.2333G>T was detected on single cell resolution via the green signal, the DNMT3A wild type via the red signal and the cell nuclei (DAPI) via the blue signal. DAPI: 4′,6-Diamidin-2-phenylindole; EEL: external elastic lamina; FFPE: formalin-fixed paraffin embedded; IEL: internal elastic lamina; LU: lumen; mutaFISH: mutation-specific Fluorescence In Situ Hybridization.





Figure 3 — Differentially expressed genes in TET2 CHIP mutation carriers (n=3) versus age and sex matched non-mutation controls (n=21) were enriched in darkgreen module in STARNET macrophage RNAseq data. Left upper panel: Volcano plot of differentially expressed genes between TET2 CHIP mutation carriers versus age and sex matched non-mutation controls in STARNET CAD cases. Differentially expressed genes were highlighted in lightblue. Top upregulated and downregulated genes with the smallest p-values or with the biggest log2 fold changes were labeled with gene names. Differentially expressed genes that overlap with darkgreen module genes were highlighted in darkgreen. Left bottom panel: Top 10 enriched gene ontologies for differentially expressed genes in TET2 CHIP mutation carriers versus non-mutation controls. Bonferroni corrected p<0.05 was considered statistically significant. Right upper panel: Visualization of darkgreen module inferred from STARNET macrophage RNAseq data. Top key drivers were highlighted in yellowgreen. Right bottom panel: Dot plot indicating the association of darkgreen module genes with clinical traits. P-value <0.05 (-log10(p) >1.3, cut off was indicated by vertical red line) is considered statistically significant.GO: Gene Ontology; BP: biological pathway; CC: cellular component; MF: molecular function.



**Figure 4** – Differentially expressed genes in ASXL1 CHIP mutation carriers (n=3) versus age and sex matched non-mutation controls (n=27) were enriched in black module in STARNET macrophage RNAseq data. **Left upper panel**: Volcano plot of differentially expressed genes (DEGs) between ASXL1 CHIP mutation carriers versus age and sex matched non-mutation controls in STARNET CAD cases. Differentially expressed genes were highlighted in pink. Top upregulated and downregulated genes with the smallest p-values or with the biggest log2 fold changes were labeled with gene names. Differentially expressed genes that overlap with black module genes were highlighted in black. **Left bottom panel**: Top 10 enriched gene ontology (GO) terms for differentially expressed genes in ASXL1 CHIP mutation carriers versus non-mutation controls. Bonferroni corrected p<0.05 was considered statistically significant. **Right upper panel**: Visualization of black module inferred from STARNET macrophage RNAseq data. Top key drivers were highlighted in pink. **Right bottom panel**: Dot plot for the association of black module genes with clinical traits. P-value <0.05 (-log10(p) >1.3, cut off was indicated by vertical red line) is considered statistically significant. GO: Gene Ontology; BP: biological pathway; CC: cellular component; MF: molecular function.